CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
79 hedge funds and large institutions have $76.7M invested in CTI BioPharma Corp. (DE) Common Stock in 2018 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 21 reducing their positions, and 15 closing their positions.
467% more call options, than puts
Call options by funds: $119K | Put options by funds: $21K
5% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 21
5% less funds holding
Funds holding: 83 → 79 (-4)
27% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 15
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
62% less capital invested
Capital invested by funds: $200M → $76.7M (-$124M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.44M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.1M |
| 3 |
JP Morgan Chase
New York
|
+$570K |
| 4 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$489K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$386K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$17.3M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.36M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.75M |
| 4 |
Millennium Management
New York
|
-$3.37M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.01M |
CTIC Hedge Fund Activity: Q3 2018 in Review
79 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q3 2018, worth a combined $76.7M — down 62% from $200M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of CTIC and 11 opened new positions — a net loss of 4 holders — while 21 trimmed existing stakes and 22 added.
The largest buyer was Opaleye Management, adding an estimated $3.44M. The largest seller was Franklin Resources, exiting entirely with an estimated $17.3M sold.
- 79 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q3 2018, down from 83 in Q2 2018.
- Funds reported $76.7M of CTI BioPharma Corp. (DE) Common Stock stock for Q3 2018, down 62% quarter-over-quarter.
- 11 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q3 2018 and 15 closed out, a net change of -4 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q3 2018 was Opaleye Management, an estimated $3.44M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q3 2018 was Franklin Resources, an estimated $17.3M sold.
Based on aggregated 13F filings for Q3 2018.